Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Dezima In-Licenses CETP Inhibitor Program from MTPC

Published: Thursday, April 25, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
World-renowned dyslipidemia experts join Dezima’s Scientific Advisory Board.

Dezima Pharma (‘Dezima’) has announced the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.

DEZ-001 has completed single and multiple ascending dose studies showing an unprecedented effect on high density lipoprotein (HDL) and low density lipoprotein (LDL) levels in healthy volunteers with a very favourable side-effect profile.

The company plans to support clinical development of DEZ-001 to Phase 3 clinical trials.

Professor John Kastelein, founder of Dezima, co-founder of UniQure and advisor to Forbion Capital Partners, identified DEZ-001 as a potentially best-in-class, potent and safe CETP inhibitor.

At the same time, Dezima also reported the strengthening of its Scientific Advisory Board (SAB) with the addition of two world-leading experts in the dyslipidemia space: Dr Philip Barter, President of the International Atherosclerosis Society and Conjoint Professor at The University of New South Wales, Sydney, Australia, and Dr Bryan Brewer, Director at Washington Cardiovascular Associates and Senior Research Consultant of Lipoprotein and Atherosclerosis Research at the Medstar Research Institute, Washington DC, USA.

Professor Kastelein, Dezima’s CSO and Chairman of its SAB, commented: “CETP inhibitors hold enormous potential to further normalize lipid levels in millions of dyslipidemic patients worldwide. This product was a compelling in-licensing prospect because of its promising early clinical efficacy and safety profile. By applying a smart development program, DEZ-001 could potentially enter the market at a time similar to competing CETP inhibitors.”

Sander van Deventer, Dezima’s interim-CEO and General Partner at Forbion Capital Partners, who seed-financed Dezima together with BioGeneration Ventures, added: “The dyslipidemia space represents an attractive investment opportunity due to the continued high unmet medical need and the introduction of several next-generation therapeutic approaches. The addition of these two renowned experts to Dezima’s SAB will support the company in advancing DEZ-001, and in helping to identify additional earlier-stage dyslipidemia assets in order to develop a range of promising therapies in the CVD field.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dezima Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001
TULIP study will investigate the effects of different doses of DEZ-001 on CVD biomarkers.
Friday, August 30, 2013
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos